Israel - hebraisk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 100 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Israel - hebraisk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 50 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Israel - hebraisk - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 200 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less.management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrain

Israel - hebraisk - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 135 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

Israel - hebraisk - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 180 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

Israel - hebraisk - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Israel - hebraisk - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Israel - hebraisk - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Israel - hebraisk - Ministry of Health

אפריל רשת חנויות בעמ - איפור

Israel - hebraisk - Ministry of Health

אפריל רשת חנויות בעמ - איפור